Intlekofer, Andrew M <br/><br/>
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.  [electronic resource] 

 -  Journal of leukocyte biology  Jul 2013 
 - 25-39 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Review 
<br/><br/><label>ISSN: </label>1938-3673 
<br/><br/><label>Standard No.: </label>10.1189/jlb.1212621  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Blocking--therapeutic use<br/>CTLA-4 Antigen--antagonists & inhibitors<br/>Drug Evaluation, Preclinical<br/>Humans<br/>Immunotherapy<br/>Neoplasms--immunology<br/>Programmed Cell Death 1 Receptor--antagonists & inhibitors